A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Eligible for screening study DCP 001
EA8143 is closed to new patient accrual effective June 2, 2021.
Quality of Life (QOL) component reached its accrual goal. Therefore, QOL is closed to new patient accrual effective June 19, 2020.
Site Delegation of Tasks Log required prior to registration of any patients.